Philip Sauvageau, MD
Internal Medicine · Niagara Falls, NYNPI 1609852714
Payments from drug & device makers
Across 236 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$570
- Boehringer Ingelheim$522
- Novo Nordisk$373
- Pfizer$354
- GSK$282
- Johnson & Johnson$175
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,904100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 36 | $570 |
| Boehringer Ingelheim | 25 | $522 |
| Novo Nordisk | 27 | $373 |
| Pfizer | 19 | $354 |
| GSK | 18 | $282 |
| Johnson & Johnson | 13 | $175 |
| Merck | 10 | $163 |
| UCB, Inc. | 6 | $152 |
| E.r. Squibb & Sons, L.L.C. | 8 | $143 |
| AstraZeneca | 8 | $120 |
| Novartis | 7 | $106 |
| Dexcom, Inc. | 5 | $100 |
| Amarin Pharma, Inc. | 6 | $90 |
| GE HealthCare | 6 | $80 |
| Indivior Inc. | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $58 |
| Currax Pharmaceuticals LLC | 3 | $39 |
| Grifols USA, LLC | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Gilead | 2 | $33 |
| Amgen | 2 | $33 |
| AbbVie(2 entities) | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Boston Scientific | 1 | $29 |
| SK Life Science, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 2 | $26 |
| Abbott | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Bayer | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$3,904 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 839 | $193,561 |
| XareltoRivaroxaban | 660 | $120,526 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $109,634 |
| AustedoDeutetrabenazine | 20 | $105,404 |
| TrulicityDulaglutide | 68 | $76,469 |
| JardianceEmpagliflozin | 246 | $50,759 |
| TradjentaLinagliptin | 166 | $45,129 |
| Glatiramer Acetate | 24 | $29,989 |
| MounjaroTirzepatide | 28 | $28,020 |
| LinzessLinaclotide | 41 | $27,795 |
| FarxigaDapagliflozin Propanediol | 109 | $20,356 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $19,500 |
| MyrbetriqMirabegron | 102 | $19,177 |
| NuedextaDextromethorphan Hbr/Quinidine | 55 | $17,776 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $354 | $201,646864 claims |
| Johnson & JohnsonXarelto | $175 | $120,526660 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $16 | $105,40420 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $570 | $104,48996 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $522 | $101,876423 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $120 | $39,856138 claims |
| AbbVieLinzess, Lumigan | $31 | $34,15363 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $282 | $28,84453 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $34 | $11,94633 claims |
| Novo NordiskOzempic | $373 | $11,77812 claims |
| NovartisEntresto | $106 | $11,46263 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $18 | $9,30463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Niagara Falls
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.